Worldwide Clinical Trials Selects TransPerfect's Trial Interactive Platform as its eTMF Solution
TransPerfect
, a leading provider of e-clinical technologies to the
life sciences
industry, today announced that
Worldwide Clinical Trials
(WCT) has selected
Trial Interactive
as its electronic Trial Master File (eTMF) solution to streamline global study management. Trial Interactive is a web-based, 21 CFR Part 11 compliant platform that eliminates the redundancies inherent in paper-based TMF studies.
“With Trial Interactive as our eTMF solution, we will be able to deliver near real-time access to eTMFs for our clients, and we will improve overall processes in managing TMF documentation,” said Tom Wardle, Chief Operating Officer of WCT.
By providing study stakeholders with real-time access to
clinical trial documentation
, Trial Interactive eliminates travel and shipping costs associated with review and reconciliation, thereby streamlining clinical development programs for WCT and its sponsors. In addition, Trial Interactive’s interface is available in more than 20 languages, which will enable WCT to deploy the solution in the local language of the end user, including global study teams, sponsors, and investigative site personnel.
Michael Smyth, General Manager of TransPerfect Life Sciences Solutions, added, “We are proud that WCT has chosen Trial Interactive as its eTMF solution, and we’re pleased to support their ultimate goal of a paperless clinical trial.”
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
